Regulation Tracker
Tracking FDA, state, and international rules that govern compounded peptides, telehealth prescribing, and sports anti-doping status.
503A vs. 503B Compounding: What the Difference Means for Peptides
How 503A pharmacies and 503B outsourcing facilities differ under US law, and why that split affects whether a compounded peptide is available at all.
FDA Compounding Rulings in 2025: A Peptide-Focused Recap
A plain-language recap of how FDA compounding policy affecting peptides moved through 2025, with pointers to where to verify the current record.
FDA Compounding Rulings: 2026 Update for Peptide Watchers
A running 2026 update on FDA peptide compounding policy, covering what stays constant, what to watch for, and where to check the current record.
Peptide Regulation in Australia: The TGA's Role, Explained
How the Therapeutic Goods Administration classifies peptides, why scheduling and personal importation rules matter, and where to check current status.
Peptide Regulation in Canada: Health Canada's Role, Explained
How Health Canada classifies unapproved peptides, why compounding standards matter, and where Canadians can check a substance's current status.
Peptide Regulation in the EU: How the System Is Structured
How EU medicines law classifies research peptides, why national agencies matter as much as EMA, and where to check a substance's current status.
Peptides on WADA's Prohibited List: What Athletes Should Know
Which categories of peptides fall under the WADA Prohibited List, why status can differ from a country's medical legality, and how to check the current list.
The FDA's Category 2 Bulk Substances List, Explained
What the FDA's Category 2 list of bulk drug substances means for compounding pharmacies, and why several popular peptides are on it.
UK Peptide Regulation: The MHRA's Role, Explained
How the MHRA regulates peptides in the UK, the 'specials' route for unlicensed medicines, and what that means for a peptide's actual availability.